公开(公告)号：EP1423115B9

公开(公告)日：2009-09-02

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

公开(公告)号：EP1423115B1

公开(公告)日：2009-04-15

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

摘要翻译： 本发明包含有效抑制血管生成的一组化合物。 更具体地说，氮取代的沙利度胺类似物和二取代的沙利度胺类似物已被证明可抑制血管生成。 重要的是，这些化合物可以口服给药。

公开(公告)号：EP1423115A2

公开(公告)日：2004-06-02

申请号：EP02757019.1

申请日：2002-08-06

申请人： The Children's Medical Center Corporation ,  EntreMed, Inc.

发明人： SHAH, Jamshed, H. ,  CONNER, Barry, P. ,  SWARTZ, Glenn., M., Jr. ,  HUNSUCKER, Kimberly, A. ,  ROUGAS, John ,  D'AMATO, Robert ,  PRIBLUDA, Victor ,  TRESTON, Anthony

IPC分类号： A61K31/454

CPC分类号： C07D401/04 ,  A61K31/454

摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substitutued thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

公开(公告)号：EP1343803A2

公开(公告)日：2003-09-17

申请号：EP01968112.1

申请日：2001-08-24

申请人： EntreMed, Inc.

发明人： AGOSTON, Gregory ,  SHAH, Jamshed, H. ,  HUNSUCKER, Kimberly, A. ,  PRIBLUDA, Victor ,  LAVALLEE, Theresa, M. ,  GREEN, Shawn, J. ,  HERBSTRITT, Christopher, J. ,  ZHAN, Xiaoguo, H. ,  TRESTON, Anthony

IPC分类号： C07J1/00 ,  C07J13/00 ,  C07J41/00 ,  C07J9/00 ,  C07J3/00 ,  C07J7/00 ,  A61K31/56 ,  A61P35/00

CPC分类号： C07J1/00

摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.